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Table 1
Bivariate Regressions: Outcome ¼ Nominated VAS @ 12 weeks controlling for
baseline values
Variable N in
analysis
b coefﬁcient (95% CI) p-value
BMI 106 -0.01 (-0.09 to 0.07) 0.79
Gender (female) 113 -0.80 (-1.64 to 0.04) 0.06
Age 113 0.00 (-0.06 to 0.05) 0.88
KOOS Pain Subscale Score 113 -0.03 (-0.06 to 0.00) 0.05
Pain on nominated Activity
VAS at baseline
113 0.68 (0.50 to 0.87) <0.001
IPQ-B Overall Score 111 0.02 (-0.03 to 0.07) 0.46
HAD Anxiety Score 111 -0.01 (-0.12 to 0.10) 0.90
HAD Depression Score 111 0.10 (-0.02 to 0.22) 0.12
Total Bone Marrow Lesion Volume* 112 -0.02 (-0.09 to 0.04) 0.47
PF Bone Marrow Lesion Volume* 112 -0.13 (-0.24 to -0.01) 0.04
Synovial Tissue Volume* 97 0.00 (-0.03 to 0.04) 0.87
Number of hours of daily
brace wearing @ 6 weeks
105 -0.15 ( -0.31 to 0.01) 0.06
Number of hours of daily
brace wearing @ 12 weeks
101 0.01 ( -0.15 to 0.13) 0.88
*Coefﬁcients for volume changes have been rescaled to reﬂect an increase of
1000mm3
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A390The IPFP volume loss in the DþE group was signiﬁcantly greater than
that in the E [control] group (p¼0.03) when not adjusting for 3 parallel
comparisons; other between-group differences in longitudinal changes
were not statistically signiﬁcant. Change in IPFP volume appeared to be
more strongly driven by a change in anterior surface area than in
thickness (Table 1). Across the intervention groups, there was a sig-
niﬁcant correlation between IPFP volume change and weight loss
(r¼0.40), BMI change (r¼0.39), total body fat mass change with DXA
(r¼0.44; n¼88), subcutaneous thigh fat changewith CT (r¼0.32; n¼82),
and inter-muscular thigh fat change with CT (r¼0.29; n¼82).
Conclusions: In this ﬁrst study investigating the effect of exercise and/
or diet on IPFP morphology, we observed a signiﬁcant reduction of
intra-articular fat mass (IPFP) in all intervention groups. The combi-
nation of diet and exercise appeared to be more effective in reducing
IPFP volume than exercise alone. Per regression analysis, there was a
0.27% reduction in IPFP volume for each % weight lost. Limitations to
this study include the lack of a true control group (one without an
exercise or dietary intervention component), and the fact that only a
subsample of the IDEA trial was studied using MR imaging. The IPFP
having been described as a potential source of inﬂammatory cytokines
motivates further exploration of the relationship between IPFP volume
change, improvement in clinical outcomes, and their relationship to
inﬂammatory markers.
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Purpose: Patellofemoral joint osteoarthritis (PFJOA) is associated with
pain, stiffness and functional limitation (Duncan et al. 2009, Crossley
and Hinman 2011). Our previous clinical trial of a brace on PFJOA
showed clinically signiﬁcant improvements in pain (Callaghan et al.
2013) after 6 and 12 weeks of daily brace wearing. Patellar braces are
thin and prolonged daily use was common; they might be appealing
especially to those likely to improve. However, there is little evidence as
to who is likely to beneﬁt from a patellar brace. Our goal was to study
the relationship between subjects’ baseline characteristics and clinical
outcomes to help identify and target those who would beneﬁt most
from brace treatment in PFJOA.
Methods: Subjects age 40-70 years old with knee pain were included if
they had a radiographic K-L score grade 2 or 3 in the PFJ which was
greater than K-L score for the tibiofemoral compartments. Subjects had
to have symptomatic PFJOA and tenderness over lateral or medial
patellar facet on palpation or a positive patellar compression test. Pain
must have been present daily for the previous 3 months and above a
score of 40 on a VAS (0 ¼ 100mm for their nominated most aggravating
activity (VASNA). After an initial 6 week controlled trial of brace versus
no brace, we carried out an open label follow-up where all subjects
received brace for 12 weeks with a Bioskin Patellar Tracking Q Brace
(Ossur UK, Manchester, England). All subjects had contrast enhanced
magnetic resonance imaging (CE-MRI) at baseline from which we
measured bone marrow lesion (BML) volume at the PFJ. The primary
outcome measures were pain responder status and pain recorded by
the VASNA (0-100mm where 100 is worst pain). The nominated activ-
ities typically were: stairs ascent, stairs descent, squatting, kneeling,
slope walking. Variables entered into the model were Body Mass Index
(BMI), baseline VASNA, the number of hours daily of wearing the brace,
age, and gender. Analysis looked at the pain using the VASNA after 12
weeks of brace treatment (Open label data), to see which selected
factors best correlated with the VASNA. Firstly, bivariate linear regres-
sion looked at demographics, KOOS questionnaire scores, HAD, IPQ-B,
and CE-MRI PFJ MRI volumes and the baseline VASNA score. Multiple
linear regression was done that included factors that reached statistical
signiﬁcance in bivariate analyses to see which variables were inde-
pendently associated with pain at 12 weeks.
Results: 126 subjects with PFJOA were eligible (mean age 55.48 (SD
7.49) years; 72 females (57.14%); BMImedian 29.75 (IQR 26.49 to 34.89);
median baseline VASNA 68mm (IQR 53 to 81). Bivariate analysis
revealed four factors that emerged as signiﬁcant or near signiﬁcant
predictors of low VASNA at 12 weeks, namely: female gender, lower
baseline VASNA, and higher baseline PFJ BML volume, and at 6 weeks
more brace use (see table). Multiple linear regression revealed that
gender (p¼.04), brace use at 6 weeks (p¼.05) and lower baseline VASNA(P<0.001) all predicted VASNA at 12 weeks, although the effect of PFJ
BML volume, became non-signiﬁcant. The effect of brace usage at 6
weeks on painwas large in that for each one extra hour of use, therewas
a decrease of pain VASNA of 15mm.
Conclusions: A low baseline pain based on VASNA was a predictor of a
low VASNA after 12 weeks of brace wearing in PFJOA. Women, and
those using the brace more were also more likely to show lower VASNA
scores.649
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Purpose: Exercise is one of the established treatment method for knee
osteoarthritis (OA). However, the mechanisms of its action is not fully
understood. Although exercise has a muscle strengthening effect that
may improve the stability of the knee joint, it has been speculated that
exercise may exert anti-inﬂammatory effect for the joint. The aim of this
study was to examine whether exercise had the anti-inﬂammatory
effects for the joint in clinical practice using biomarkers for
inﬂammation.
Methods: This study was approved by the Ethics Committee of our
university and conducted in accordance with the declaration of Hel-
sinki. The written informed consent for this study participation was
obtained from all subjects. A total of one-hundred twenty post-
menopausal womenwith medial type of primary knee OA (K/L2-4) who
ﬁrst visited our outpatient clinic for knee pain were included in the
study. Subjects were randomized to either the exercise therapy group or
the control group. The patients in the exercise therapy group conducted
three different kinds of home exercise and stretching. The patients in
the control group took either the oral selective COX2 inhibitor (cele-
coxib, 200mg/day for 12 weeks) or the intra-articular injection of
hyaluronic acid (HA)(high molecular weight 2700kDa HA, 5 times with
one week interval). Age, body mass index (BMI), Japanese Knee
Osteoarthritis Measure (JKOM) score, visual analog scale (VAS) for pain
score and serum levels of biomarkers for inﬂammation (high-sensitivity
C-reactive protein [hs-CRP] and interleukin [IL]-6) were evaluated at
baseline and 12 weeks after treatment initiation. Values in each group
were compared between baseline and 12 weeks using a paired t-test.
Results: The sixty-nine of 120 patients were assigned to either the
exercise therapy group and the remaining ﬁfty-one patients were to the
control group. During the twelveweeks of examination, twelve patients
in the exercise therapy group and the eight patients in the control group
were withdrawn. No signiﬁcant differences of the baseline
